Research ExplorerPublicationsOutcome of transplantation for myelofibrosis.

Outcome of transplantation for myelofibrosis.

Standard

Outcome of transplantation for myelofibrosis. / Ballen, Karen K; Shrestha, Smriti; Sobocinski, Kathleen A; Zhang, Mei-Jie; Bashey, Asad; Bolwell, Brian J; Cervantes, Francisco; Devine, Steven M; Gale, Robert Peter; Gupta, Vikas; Hahn, Theresa E; Hogan, William J; Kröger, Nicolaus; Litzow, Mark R; Marks, David I; Maziarz, Richard T; McCarthy, Philip L; Schiller, Gary; Harry, C Schouten; Roy, Vivek; Wiernik, Peter H; Horowitz, Mary M; Giralt, Sergio A; Arora, Mukta.

In: BIOL BLOOD MARROW TR, Vol. *16*, No. 3, 3, 2009, p. 358-367.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ballen, KK, Shrestha, S, Sobocinski, KA, Zhang, M-J, Bashey, A, Bolwell, BJ, Cervantes, F, Devine, SM, Gale, RP, Gupta, V, Hahn, TE, Hogan, WJ, Kröger, N, Litzow, MR, Marks, DI, Maziarz, RT, McCarthy, PL, Schiller, G, Harry, CS, Roy, V, Wiernik, PH, Horowitz, MM, Giralt, SA & Arora, M 2009, 'Outcome of transplantation for myelofibrosis.', BIOL BLOOD MARROW TR, vol. *16*, no. 3, 3, pp. 358-367. <http://www.ncbi.nlm.nih.gov/pubmed/19879949?dopt=Citation>

APA

Ballen, K. K., Shrestha, S., Sobocinski, K. A., Zhang, M-J., Bashey, A., Bolwell, B. J., Cervantes, F., Devine, S. M., Gale, R. P., Gupta, V., Hahn, T. E., Hogan, W. J., Kröger, N., Litzow, M. R., Marks, D. I., Maziarz, R. T., McCarthy, P. L., Schiller, G., Harry, C. S., ... Arora, M. (2009). Outcome of transplantation for myelofibrosis. BIOL BLOOD MARROW TR, *16*(3), 358-367. [3]. http://www.ncbi.nlm.nih.gov/pubmed/19879949?dopt=Citation

Vancouver

Ballen KK, Shrestha S, Sobocinski KA, Zhang M-J, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. BIOL BLOOD MARROW TR. 2009;*16*(3):358-367. 3.

Bibtex

@article{58f0fd52e89f4475b8646901d22d9f44,
title = "Outcome of transplantation for myelofibrosis.",
abstract = "Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease free survival after allogeneic hematopoietic cell transplantation. In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA non-identical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft versus host disease prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day transplant related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5 year overall survival rates were 37%, 30%, and 40% respectively. Disease-free survival rates were 33%, 27% and 22% respectively. Disease-free survival for patients receiving reduced intensity transplants was comparable, 39% for HLA identical sibling donors and 17% for unrelated donors at three years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival in about one-third of patients.",
author = "Ballen, {Karen K} and Smriti Shrestha and Sobocinski, {Kathleen A} and Mei-Jie Zhang and Asad Bashey and Bolwell, {Brian J} and Francisco Cervantes and Devine, {Steven M} and Gale, {Robert Peter} and Vikas Gupta and Hahn, {Theresa E} and Hogan, {William J} and Nicolaus Kr{\"o}ger and Litzow, {Mark R} and Marks, {David I} and Maziarz, {Richard T} and McCarthy, {Philip L} and Gary Schiller and Harry, {C Schouten} and Vivek Roy and Wiernik, {Peter H} and Horowitz, {Mary M} and Giralt, {Sergio A} and Mukta Arora",
year = "2009",
language = "Deutsch",
volume = "*16*",
pages = "358--367",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Outcome of transplantation for myelofibrosis.

AU - Ballen, Karen K

AU - Shrestha, Smriti

AU - Sobocinski, Kathleen A

AU - Zhang, Mei-Jie

AU - Bashey, Asad

AU - Bolwell, Brian J

AU - Cervantes, Francisco

AU - Devine, Steven M

AU - Gale, Robert Peter

AU - Gupta, Vikas

AU - Hahn, Theresa E

AU - Hogan, William J

AU - Kröger, Nicolaus

AU - Litzow, Mark R

AU - Marks, David I

AU - Maziarz, Richard T

AU - McCarthy, Philip L

AU - Schiller, Gary

AU - Harry, C Schouten

AU - Roy, Vivek

AU - Wiernik, Peter H

AU - Horowitz, Mary M

AU - Giralt, Sergio A

AU - Arora, Mukta

PY - 2009

Y1 - 2009

N2 - Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease free survival after allogeneic hematopoietic cell transplantation. In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA non-identical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft versus host disease prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day transplant related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5 year overall survival rates were 37%, 30%, and 40% respectively. Disease-free survival rates were 33%, 27% and 22% respectively. Disease-free survival for patients receiving reduced intensity transplants was comparable, 39% for HLA identical sibling donors and 17% for unrelated donors at three years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival in about one-third of patients.

AB - Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease free survival after allogeneic hematopoietic cell transplantation. In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA non-identical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft versus host disease prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day transplant related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5 year overall survival rates were 37%, 30%, and 40% respectively. Disease-free survival rates were 33%, 27% and 22% respectively. Disease-free survival for patients receiving reduced intensity transplants was comparable, 39% for HLA identical sibling donors and 17% for unrelated donors at three years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival in about one-third of patients.

M3 - SCORING: Zeitschriftenaufsatz

VL - *16*

SP - 358

EP - 367

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 3

M1 - 3

ER -